Cognition Therapeutics (CGTX) Stock Overview
A clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
CGTX Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Cognition Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.74 |
| 52 Week High | US$3.83 |
| 52 Week Low | US$0.22 |
| Beta | 1.23 |
| 1 Month Change | -2.79% |
| 3 Month Change | -28.40% |
| 1 Year Change | 332.84% |
| 3 Year Change | -38.08% |
| 5 Year Change | n/a |
| Change since IPO | -86.37% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Nov 12
We're A Little Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Jul 04Cognition Therapeutics (NASDAQ:CGTX) Will Have To Spend Its Cash Wisely
Dec 20Can Cognition Therapeutics (NASDAQ:CGTX) Afford To Invest In Growth?
Sep 06Cognition Therapeutics: Shines Less Bright After Phase 2 Results In Alzheimer's Disease
Jul 31Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?
May 22Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's
Apr 18Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation
Nov 30Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?
Aug 15Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans
Mar 17Cognition stock rises 12% on $2.14M grant from NIH for Alzheimer's study
Sep 27We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth
Aug 12Cognition's Alzheimer's candidate demonstrates mechanism of action; shares soar
Aug 05We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Mar 19Shareholder Returns
| CGTX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 25.2% | 2.7% | 4.1% |
| 1Y | 332.8% | 20.6% | 12.6% |
Return vs Industry: CGTX exceeded the US Pharmaceuticals industry which returned 20.6% over the past year.
Return vs Market: CGTX exceeded the US Market which returned 12.6% over the past year.
Price Volatility
| CGTX volatility | |
|---|---|
| CGTX Average Weekly Movement | 15.6% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CGTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CGTX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 27 | Lisa Ricciardi | www.cogrx.com |
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer’s disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
Cognition Therapeutics, Inc. Fundamentals Summary
| CGTX fundamental statistics | |
|---|---|
| Market cap | US$153.60m |
| Earnings (TTM) | -US$27.99m |
| Revenue (TTM) | n/a |
Is CGTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CGTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$27.99m |
| Earnings | -US$27.99m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.32 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CGTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/30 20:41 |
| End of Day Share Price | 2025/11/28 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cognition Therapeutics, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Wood | B. Riley Securities, Inc. |
| Mayank Mamtani | B. Riley Securities, Inc. |
| null null | B. Riley Securities, Inc. |